廣告
香港股市 已收市

  • 恒指

    17,718.61
    +2.14 (+0.01%)
     

  • 國指

    6,331.86
    +7.81 (+0.12%)
     

  • 上證綜指

    2,967.40
    +21.55 (+0.73%)
     

  • 滬深300

    3,461.66
    +7.54 (+0.22%)
     

  • 美元

    7.8080
    -0.0008 (-0.01%)
     

  • 人民幣

    0.9302
    -0.0001 (-0.01%)
     

  • 道指

    39,118.86
    -45.20 (-0.12%)
     

  • 標普 500

    5,460.48
    -22.39 (-0.41%)
     

  • 納指

    17,732.60
    -126.08 (-0.71%)
     

  • 日圓

    0.0483
    -0.0001 (-0.10%)
     

  • 歐元

    8.3628
    +0.0049 (+0.06%)
     

  • 英鎊

    9.8710
    +0.0020 (+0.02%)
     

  • 紐約期油

    81.46
    -0.28 (-0.34%)
     

  • 金價

    2,336.90
    +0.30 (+0.01%)
     

  • Bitcoin

    60,669.79
    -815.67 (-1.33%)
     

  • CMC Crypto 200

    1,264.82
    -19.01 (-1.48%)
     

OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
·2 分鐘文章

OrthoPediatrics (KIDS) reported $44.69 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 41.5%. EPS of -$0.30 for the same period compares to -$0.29 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $41.63 million, representing a surprise of +7.35%. The company delivered an EPS surprise of +28.57%, with the consensus EPS estimate being -$0.42.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product sales by category- Trauma and deformity: $33.30 million versus the three-analyst average estimate of $29.68 million. The reported number represents a year-over-year change of +42.4%.

  • Product sales by category- Sports medicine/other: $1.18 million versus $1.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.

  • Product sales by category- Scoliosis: $10.20 million versus $9.13 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +44.3% change.

View all Key Company Metrics for OrthoPediatrics here>>>

Shares of OrthoPediatrics have returned +19.5% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research